Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | GABBR2 | O75899 | 3/20 | 0.35 |
| ▸ | GABBR1 | Q9UBS5 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Arbaclofen Placarbil SCHEMBL351833 | 0.91 | GABBR2 (0.47) | MAPTL3MBTL1RAB9ACYP2C9MEN1 | |
| Arbaclofen Placarbil SCHEMBL638204 | 0.91 | GABBR2 (0.47) | MAPTL3MBTL1RAB9ACYP2C9MEN1 | |
| Arbaclofen Placarbil SCHEMBL349961 | 0.91 | GABBR2 (0.47) | MAPTL3MBTL1RAB9ACYP2C9MEN1 | |
| Arbaclofen Placarbil SCHEMBL3375708 | 0.91 | GABBR2 (0.47) | MAPTL3MBTL1RAB9ACYP2C9MEN1 | |
| Arbaclofen Placarbil SCHEMBL2472988 | 0.91 | GABBR2 (0.47) | MAPTL3MBTL1RAB9ACYP2C9MEN1 | |
| Arbaclofen Placarbil SCHEMBL14689524 | 0.89 | GABBR2 (0.46) | MAPTL3MBTL1RAB9ACYP2C9MEN1 | |
| Arbaclofen Placarbil SCHEMBL14692761 | 0.89 | GABBR2 (0.46) | MAPTL3MBTL1RAB9ACYP2C9MEN1 | |
| Arbaclofen Placarbil SCHEMBL14689601 | 0.89 | GABBR2 (0.46) | MAPTL3MBTL1RAB9ACYP2C9MEN1 | |
| Arbaclofen Placarbil SCHEMBL636876 | 0.88 | MAPT (0.39) | MAPTL3MBTL1RAB9ACYP2C9MEN1 | |
| Arbaclofen Placarbil SCHEMBL638830 | 0.88 | MAPT (0.39) | MAPTL3MBTL1RAB9ACYP2C9MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9265748-B2 | Anhydrous and hemihydrate crystalline forms of an (R)-baclofen prodrug, methods of synthesis and methods of use | XENOPORT, INC. (US) | 2016-02-23 | — | — | US | disclosed |
| US-20150313865-A1 | ANHYDROUS AND HEMIHYDRATE CRYSTALLINE FORMS OF AN (R)-BACLOFEN PRODRUG, METHODS OF SYNTHESIS AND METHODS OF USE | XENOPORT, INC. (US) | 2015-11-05 | — | — | US | disclosed |
| US-8580850-B2 | Anhydrous and hemihydrate crystalline forms of an (R)-baclofen prodrug, methods of synthesis and methods of use | XENOPORT, INC. (US) | 2013-11-12 | — | — | US | disclosed |
| US-20130041026-A1 | ANHYDROUS AND HEMIHYDRATE CRYSTALLINE FORMS OF AN (R)-BACLOFEN PRODRUG, METHODS OF SYNTHESIS AND METHODS OF USE | XENOPORT, INC. (US) | 2013-02-14 | — | — | US | disclosed |
| US-20100255093-A1 | SUSTAINED RELEASE ORAL DOSAGE FORMS OF AN R-BACLOFEN PRODRUG | XENOPORT, INC. (US) | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130041026-A1 | ANHYDROUS AND HEMIHYDRATE CRYSTALLINE FORMS OF AN (R)-BACLOFEN PRODRUG, METHODS OF SYNTHESIS AND METHODS OF USE | GABRB3, GABRB1, GABBR1 | MAPT 723/4885L3MBTL1 2828/4885RAB9A 930/4885 |
| US-20150313865-A1 | ANHYDROUS AND HEMIHYDRATE CRYSTALLINE FORMS OF AN (R)-BACLOFEN PRODRUG, METHODS OF SYNTHESIS AND METHODS OF USE | GABRB3, GABRB1, GABBR1 | MAPT 719/4885L3MBTL1 2876/4885RAB9A 918/4885 |
| US-20100255093-A1 | SUSTAINED RELEASE ORAL DOSAGE FORMS OF AN R-BACLOFEN PRODRUG | GABRB2, GABRB3, GABBR2 | MAPT 2583/4885L3MBTL1 1914/4885RAB9A 272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.